Aldesleukin
- Generic Name
- Aldesleukin
- Brand Names
- Proleukin
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 110942-02-4
- Unique Ingredient Identifier
- M89N0Q7EQR
- Background
Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This recombinant form differs from native interleukin-2 in the following ways: a) Aldesleukin is not glycosylated because it is derived from E. coli; b) the molecule has no N-terminal alanine; the codon for this amino acid was deleted during the genetic engineering procedure; c) the molecule has serine substituted for cysteine at amino acid position 125.
- Indication
For treatment of adults with metastatic renal cell carcinoma.
- Associated Conditions
- Metastatic Melanoma, Metastatic Renal Cell Carcinoma ( mRCC)
- Associated Therapies
- -
A Study to Evaluate the Effects of Giving Interleukin-2 (IL-2) Plus Anti-HIV Therapy to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-29
- Target Recruit Count
- 72
- Registration Number
- NCT00000889
- Locations
- π¦π·
Hospital F.J. Muniz C601-050 CRS, Ciudad de Buenos Aires, Buenos Aires, Argentina
π¦π·Hospital Italiano de Buenos Aires C601-020 CRS, Ciudad de Buenos Aires, Buenos Aires, Argentina
π¦π·Hospital de Clinicas 'Jose de San Martin' C601-040 CRS, Ciudad de Buenos Aires, Buenos Aires, Argentina
Effectiveness of Adding Interleukin-2 to Anti-HIV Drugs in Patients Recently Infected With HIV
- Conditions
- Interventions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2015-03-09
- Target Recruit Count
- 398
- Registration Number
- NCT00006441
- Locations
- πΊπΈ
University of Alabama- Birmingham, Birmingham, Alabama, United States
πΊπΈRick Hecht, San Francisco, California, United States
Effects of Giving Interleukin-2 (IL-2) Plus Anti-HIV Therapy to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-29
- Target Recruit Count
- 72
- Registration Number
- NCT00000948
- Locations
- πΉπ
Siriraj Hospital C603-020 CRS, Bangkok, Ratchathewi, Thailand
πΉπChulalongkorn Univ. Hosp. C603-010 CRS, Bangkok, Ratchathewi, Thailand
A Study to Test the Safety of Recombinant Interleukin-2 (rIL-2) in HIV-Infected Children
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-29
- Target Recruit Count
- 27
- Registration Number
- NCT00000849
- Locations
- πΊπΈ
Univ. of Colorado Denver NICHD CRS, Aurora, Colorado, United States
πΊπΈLong Beach Memorial Med. Ctr., Miller Children's Hosp., Long Beach, California, United States
πΊπΈTulane/LSU Maternal/Child CRS, New Orleans, Louisiana, United States
Safety and Effectiveness of L2-7001 (Interleukin-2) in HIV-Positive Patients Receiving Anti-HIV Therapy
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Chiron Corporation
- Target Recruit Count
- 212
- Registration Number
- NCT00002449
- Locations
- πΊπΈ
Anderson Clinical Research, Pittsburgh, Pennsylvania, United States
πΊπΈAIDS Research Alliance - Chicago, Chicago, Illinois, United States
πΊπΈNorthstar Med Clinic, Chicago, Illinois, United States
A Phase I Study of the Safety of Proleukin (Aldesleukin) in Combination With Ganciclovir and Antiretroviral Therapy in HIV Seropositive Patients With Cytomegalovirus (CMV) Retinitis
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Chiron Corporation
- Registration Number
- NCT00002321
- Locations
- πΊπΈ
Med College of Ohio, Toledo, Ohio, United States
A Phase I Study of Subcutaneously Administered Proleukin (Aldesleukin) in HIV-Infected Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Chiron Corporation
- Registration Number
- NCT00002107
- Locations
- πΊπΈ
Davies Med Ctr / c/o HIV Institute, San Francisco, California, United States
A Study to Evaluate the Use of a Protease Inhibitor and of Interleukin-2 (IL-2) in the Treatment of Early HIV Infection
- Conditions
- Interventions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2013-09-06
- Target Recruit Count
- 165
- Registration Number
- NCT00006154
- Locations
- π¨π¦
Centre Hospitalier de la Universite de Montreal (CHUM), Montreal, Quebec, Canada
π¨π¦Centre de traitment d'immunodeficience, Montreal, Quebec, Canada
π¨π¦Viridae Clinical Sciences / University of British Columbia, Vancouver, British Columbia, Canada
Interleukin-2 (IL-2), Pegylated Interferon (PEG-IFN Alfa-2b), and Ribavirin (RBV) Treatment in Patients With Hepatitis C and HIV Coinfection
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 24
- Registration Number
- NCT00015652
- Locations
- πΊπΈ
Northwestern University CRS, Chicago, Illinois, United States
πΊπΈJohns Hopkins Adult AIDS CRS, Baltimore, Maryland, United States
πΊπΈUCLA CARE Center CRS, Los Angeles, California, United States
Phase I Trial of the Combination of Zidovudine and Recombinant Interleukin-2 in Patients With Persistent Generalized Lymphadenopathy
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-03
- Target Recruit Count
- 20
- Registration Number
- NCT00000728
- Locations
- πΊπΈ
Stanford Univ School of Medicine, Stanford, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.